Physician profile
Luis S Ulloa
NPI 1457318636
$4,818.21
in general payments reported to CMS, 2019-2025
32 companies · $21.47 in 2025
The $21.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $389 · 2021: $1,069 · 2022: $734 · 2023: $511 · 2024: $185 · 2025: $21.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,049.61 | 2019-2024 | Wegovy, Saxenda, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,034.86 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $384.06 | 2021-2023 | |
| Pfizer INC. | $309.17 | 2019-2025 | |
| Amarin Pharma, INC. | $197.35 | 2019 | |
| Abbvie INC. | $180.18 | 2021-2023 | Ubrelvy |
| Abbott Laboratories | $169.64 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $153.66 | 2019-2023 | Arexvy |
| Allergan, INC. | $136.09 | 2019-2020 | |
| Lilly USA, LLC | $130.30 | 2019-2023 | Mounjaro |
| Cardiovascular Systems INC. | $129.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.72 | 2019-2021 | |
| Biotronik INC. | $115.37 | 2019 | |
| Nevro Corp. | $92.36 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.64 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $81.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $77.77 | 2019-2020 | |
| Amgen INC. | $53.21 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $50.52 | 2019-2023 | Watchman Access System |
| Astellas Pharma US INC | $36.30 | 2019 | |
| Relievant Medsystems, INC. | $35.48 | 2023 | Intracept |
| Seqirus USA INC | $27.66 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $26.94 | 2021-2022 | |
| Pacira Therapeutics, INC. | $20.54 | 2019 | |
| Exact Sciences Corporation | $17.75 | 2023 | Cologuard Collection Kit |
| Organogenesis INC. | $17.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.20 | 2022 | |
| Optinose US, INC. | $16.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2019 | |
| Medline Industries LP | $13.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.60 | 2022 | |
| Kvk-Tech, INC. | $9.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ulloa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.